After rapid decreases in the burden of disease in the developing world since 2000, funding for global health treatment and research has plateaued or is in decline. Meanwhile, the World Health Organization estimates that $150 billion is required to restore the pipeline of drugs for neglected tropical disease (NTDs) and Tuberculosis to the necessary levels.

Case studies conducted by the authors reveal a challenging landscape for private sector involvement in NTD drug and vaccine development, due to the size of investments needed and the average length of development timelines. Recommendations for future action:

  • Alignment of public funding with social return
  • Private sector late-stage investment and risk sharing
  • Public funding coordination and stewardship
  • Advanced market commitment for hookworm and schistosomiasis
  • Tiered PRV based on social return and clinical stage
  • Targeted domestic resource mobilization

Read more about neglected tropical disease research and development at Brookings